Emerging biotech company Shine-On Biomedical recently held a corporate briefing, where General Manager Hung Che Chiang announced that the company now holds two major technology platforms—trispecific antibodies and exosome-based drug delivery systems. Shine-On aims to achieve early-stage licensing deals valued at up to US$1 billion and plans to go public on the over-the-counter (OTC) market next year.
The company recently announced a licensing agreement with Esco Aster Pte. Ltd. of Singapore, granting rights for its exosome small-molecule drug loading patent in the Southeast Asia, New Zealand, and Australia markets (excluding Taiwan). The deal includes a total licensing value of NT$200 million, with an initial NT$20 million signing payment upon technology transfer, milestone payments of NT$180 million, a 5% sales royalty, and a share of sub-licensing revenues once the product reaches commercialization.
Chiang noted that Shine-On’s two technology platforms have each led to pipeline products—SOA101 and SOB100—both of which have received U.S. FDA approval for Phase I clinical trials. Patient enrollment for SOA101 has already begun in Taiwan, with preliminary efficacy data expected by year-end. SOB100, meanwhile, will soon begin clinical trials in the United States. Shine-On plans to pursue international licensing deals after completing Phase I or Phase IIa trials, once efficacy and safety data are confirmed.
It is noteworthy that while most Taiwanese biotech companies working on exosome technology focus on cosmetic or skincare applications, Shine-On Biomedical is pioneering the use of exosomes as a novel drug development platform—marking the first exosome-based new drug in Taiwan and abroad to advance to Phase I clinical trials.
According to Chiang, the majority of antibody drugs worldwide are monoclonal or bispecific antibodies, and so far, no trispecific antibody drugs have reached the market. Shine-On’s lead candidate, SOA101, initially targets five solid tumors: lung, colorectal, breast, ovarian, and head and neck cancers. The company aims to complete licensing no later than Phase IIa trials—and if successful at Phase I, the deal could be valued at US$500 million to US$1 billion.
Shine-On’s exosome-based drug delivery candidate SOB100 is further divided into two programs: SOB101, which uses exosomes to carry small-molecule drugs, demonstrated equivalent anticancer effects to Lipodox in animal models of breast cancer with only one-fourth the dosage. The second program, SOB102, utilizes exosomes to deliver nucleic acid drugs, showing strong cytotoxic effects against hard-to-treat glioblastoma (GBM) cells. The potential licensing value for SOB100 as a platform is estimated between US$300 million and US$1 billion.
Resource: 聖安生醫手握兩大技術平台 早期授權挑戰十億美元、拚明年掛牌上櫃
